对VITEK 2-Compact肺炎链球菌GP68药敏卡的性能评估

发布时间：2019-07-01 20:11

【摘要】：目的评估VITEK 2-Compact肺炎链球菌GP68药敏卡的性能,以E试验为参比方法。方法收集2015年1-12月98株肺炎链球菌,采用VITEK 2-Compact AST-GP68药敏卡进行药敏测定,结果与E试验结果进行对照。结果按CLSI标准,98株肺炎链球菌中青霉素的分类符合率(CA)为80.6%、严重错误(VME)为0、重大错误(ME)为12.2%、微小错误(mE)为7.1%;头孢曲松CA为90.8%、VME为0、ME为4.1%、mE为5.1%;头孢噻肟CA为91.8%、VME为0、ME为5.1%、mE为3.1%;美罗培南CA为85.7%、VME为0、ME为2.0%、mE为12.2%;阿莫西林、厄他培南、红霉素、四环素、氯霉素、泰利霉素、利奈唑胺、万古霉素、喹诺酮类(莫西沙星、氧氟沙星、左氧氟沙星)、甲氧苄啶-磺胺甲唑CA为100%。结论 VITEK 2-Compact AST-GP68由于检测原理缺陷使其对某些抗菌药物如青霉素、头孢曲松、头孢噻圬、美罗培南等的药敏试验结果出现假耐药现象,临床在遇到此类现象时,需采用其他方法进行复核确认。
[Abstract]:Objective to evaluate the performance of VITEK 2-Compact Streptococcus pneumoniae GP68 drug sensitive card and take E test as reference method. Methods 98 strains of Streptococcus pneumoniae from January to December 2015 were collected and tested by VITEK 2-Compact AST-GP68 drug sensitive card. The results were compared with those of E test. Results according to CLSI standard, the classification coincidence rate of penicillin, serious error (VME), serious error (ME), minor error (mE), ceftriaxone CA, ME, me, cefotaxime CA, ME and me were 80.6%, 0, 12.2% and 7.1%, 90.8%, 4.1% and 5.1%, respectively, and cefotaxime CA was 91.8%, ME was 5.1%, ME was 3.1%, and cefotaxime was 91.8%, ME was 5.1%, me was 3.1%, cefotaxime CA was 91.8%, VME was 0, ME was 5.1%, me was 3.1%. Meropenem CA was 85.7%, CA was 0, ME was 2.0%, me was 12.2%, amoxicillin, epipenem, erythromycin, tetracycline, chloramphenicol, tetracycline, chloramphenic Conclusion due to the defect of detection principle, VITEK 2-Compact AST-GP68 has false drug resistance to some antibiotics such as penicillin, ceftriaxone, cefotaxime, meropenem and so on.
【作者单位】：泸州市人民医院检验科;
【基金】：泸州市科技局课题[2013-S-46(2/6)]
【分类号】：R446.5

【相似文献】